Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivastigmine adjunctive therapy in male patients with chronic schizophrenia
IRCT20120314009297N8Phase 3Completed
- Sponsor
- Mazandaran University of Medical Sciences
- Start
- May 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-arm trial of rivastigmine in schizophrenia, sponsored by Mazandaran University of Medical Sciences. Primary endpoints: Psychotic symptom severity by PANSS at month 4, Clinical severity by CGI-S at month 4 and 6 more. Started May 2020; status: completed.
02
Drugs
rivastigmine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on IRCT20120314009297N8.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20120314009297N8.